ANI Pharmaceuticals (ANIP) Projected to Release Quarterly Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP) is anticipated to announce its Q2 2026 results before the market opens on Friday, August 7th. Analysts expect the company to post earnings of $2.04 per share and revenue of $260.1290 million for the quarter. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 7, 2026 at 8:00 AM ET.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.77. The firm had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.ANI Pharmaceuticals’s revenue was up 20.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.70 EPS. On average, analysts expect ANI Pharmaceuticals to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $80.87 on Wednesday. ANI Pharmaceuticals has a 1 year low of $64.99 and a 1 year high of $99.50. The stock has a market capitalization of $1.84 billion, a PE ratio of 20.47 and a beta of 0.44. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The stock has a 50-day simple moving average of $81.03 and a 200-day simple moving average of $79.43.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ANIP. Guggenheim reaffirmed a “buy” rating and issued a $124.00 price target on shares of ANI Pharmaceuticals in a report on Friday, July 10th. Canaccord Genuity Group started coverage on shares of ANI Pharmaceuticals in a research report on Thursday, July 16th. They set a “hold” rating and a $91.00 price objective for the company. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Finally, Weiss Ratings raised ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Six analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $105.00.

Insider Transactions at ANI Pharmaceuticals

In related news, Director Thomas Haughey sold 2,000 shares of the stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.88, for a total transaction of $161,760.00. Following the completion of the sale, the director owned 38,878 shares in the company, valued at $3,144,452.64. This represents a 4.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Patrick D. Walsh sold 10,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total transaction of $806,300.00. Following the transaction, the director directly owned 38,432 shares in the company, valued at $3,098,772.16. The trade was a 20.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 88,029 shares of company stock worth $6,954,472 over the last 90 days. Company insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Advisors Asset Management Inc. purchased a new stake in shares of ANI Pharmaceuticals during the first quarter worth approximately $28,000. Kemnay Advisory Services Inc. purchased a new position in ANI Pharmaceuticals during the 4th quarter worth $48,000. State of Wyoming purchased a new position in ANI Pharmaceuticals during the 2nd quarter worth $50,000. Tower Research Capital LLC TRC lifted its stake in shares of ANI Pharmaceuticals by 542.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,727 shares of the specialty pharmaceutical company’s stock worth $113,000 after acquiring an additional 1,458 shares during the period. Finally, Maryland State Retirement & Pension System boosted its holdings in shares of ANI Pharmaceuticals by 5.4% in the fourth quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock valued at $206,000 after acquiring an additional 134 shares in the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.